<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Sept. 08, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/4761313/musculoskeletal-pain-market-insight?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=wtj3wc&amp;utm_campaign=2345373+-+Musculoskeletal+Pain+Market+Report+2026-2036%3a+Growth+Drivers%2c+Epidemiology%2c+Key+Unmet+Needs%2c+Growth+Forecast&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Musculoskeletal Pain - Market Insight, Epidemiology, and Market Forecast - 2036">"Musculoskeletal Pain - Market Insight, Epidemiology, and Market Forecast - 2036"</a> has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of the musculoskeletal pain market across the seven major markets: the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. It examines historical and forecast epidemiology, treatment practices, market dynamics, competitive activity, patient burden, drug uptake, pricing, reimbursement, and commercial opportunities from 2022 through 2036. Musculoskeletal conditions affect approximately 1.7 billion people worldwide and remain the leading cause of disability. Low back pain contributes the greatest number of years lived with disability, while osteoarthritis, chronic neck pain, rheumatoid arthritis, fibromyalgia, and other degenerative or inflammatory disorders create substantial clinical and economic burdens. In the United States, musculoskeletal pain is estimated to affect nearly 37% of the population. Musculoskeletal Pain Market Growth Drivers The musculoskeletal pain market is expected to expand steadily through 2036, supported by population aging, increasing osteoarthritis prevalence, obesity, sedentary lifestyles, occupational risk factors, and rising demand for long-term pain management. Greater awareness of opioid-related dependence, overdose, and safety concerns is also accelerating the shift toward non-opioid analgesics, localized treatments, regenerative medicine, and potential disease-modifying therapies. Current treatments primarily control symptoms and generally have limited effects on disease progression. This creates significant opportunities for therapies that can deliver durable pain relief, improve physical function, reduce treatment frequency, and slow structural deterioration. Products with differentiated mechanisms, localized delivery, favorable safety profiles, or extended duration of benefit may secure meaningful competitive advantages. Current Musculoskeletal Pain Treatment Landscape Musculoskeletal pain management follows a multimodal, stepwise approach based on the underlying condition, pain severity, functional impairment, comorbidities, and patient characteristics. Exercise therapy, physiotherapy, patient education, weight management, manual therapy, and psychosocial interventions remain central to long-term care. Nonsteroidal anti-inflammatory drugs continue to be widely used because of their analgesic and anti-inflammatory effects. Topical formulations are increasingly recommended for localized knee and hand osteoarthritis because they can reduce systemic exposure. Acetaminophen may be used for mild pain, although its effectiveness is limited in inflammatory conditions. Opioids are generally reserved for severe acute pain or refractory cases because of dependence risks and limited long-term benefits. Intra-articular corticosteroids, viscosupplements, nerve blocks, and image-guided procedures may provide relief for selected patients. Joint replacement, spinal decompression, and other surgical procedures are typically considered for advanced disease or cases that do not respond adequately to conservative management. Diagnosis is based on medical history, physical examination, functional assessment, imaging, and laboratory testing when inflammatory or autoimmune disease is suspected. X-ray, magnetic resonance imaging, computed tomography, and ultrasonography support the identification of degenerative, structural, inflammatory, soft-tissue, and neurological abnormalities. Key Unmet Needs in Musculoskeletal Pain <ul><li>Limited availability of disease-modifying or curative therapies</li><li>Persistent burden of chronic and recurrent pain</li><li>Safety limitations associated with long-term pharmacological treatment</li><li>Need for durable functional and structural improvement</li><li>Insufficient biomarkers and patient-stratification tools</li><li>Variable access, reimbursement, adherence, and treatment outcomes</li></ul> Approved Musculoskeletal Pain Therapies ZILRETTA, an extended-release formulation of triamcinolone acetonide developed by Flexion, is approved for osteoarthritis knee pain. Its microsphere-based formulation enables sustained intra-articular exposure and longer symptom control than conventional corticosteroid injections. The therapy received US Food and Drug Administration approval in October 2017 following Phase III results demonstrating significant improvements in knee pain. ZILRETTA generated USD 116.6 million in 2025 sales, reflecting continued demand for localized, non-opioid pain management. LOQOA TAPE, developed by Taisho Pharmaceutical and TOKUHON Corporation, is a transdermal S-flurbiprofen and mentha oil formulation approved in Japan for osteoarthritis pain and inflammation. The product received Japanese approval in September 2015 and launched in January 2016. Its localized delivery supports continued use within Japan's osteoarthritis treatment market. Viscosupplementation products, including DUROLANE and Synvisc-One, also maintain an established market presence. Single-injection regimens and longer-lasting benefits may offer convenience and economic advantages over products requiring multiple administrations. Musculoskeletal Pain Pipeline and Emerging Therapies The musculoskeletal pain pipeline is shifting toward non-opioid analgesics, regenerative treatments, long-acting intra-articular therapies, and disease-modifying osteoarthritis drug candidates. Stem cell-based therapies, monoclonal antibodies, novel small molecules, and sustained-release formulations are being evaluated for their potential to improve symptoms while addressing structural disease progression. Mesoblast is developing rexlemestrocel-L for chronic low back pain associated with disc degeneration. The regenerative therapy is intended for patients who have exhausted conservative options and may otherwise require invasive surgery. In April 2026, Mesoblast outlined development milestones that included pivotal enrollment completion, top-line data anticipated in 2027, a planned Biologics License Application submission, and a potential US launch subject to successful clinical and regulatory outcomes. Taiwan Liposome Company is evaluating TLC599, a sustained-release dexamethasone sodium phosphate formulation, in Phase III development for knee osteoarthritis. The therapy is designed to provide rapid and prolonged pain control following local administration. In April 2026, the company presented exploratory structural-benefit data at the OARSI World Congress, supporting continued investigation of TLC599 as a potential disease-modifying osteoarthritis therapy. Biosplice Therapeutics announced in January 2026 that it had submitted a New Drug Application to the FDA for lorecivivint in knee osteoarthritis. Other companies active in the musculoskeletal pain competitive landscape include Centrexion Therapeutics, Flexion, Taisho Toyama Pharmaceutical, Mesoblast, Taiwan Liposome Company, and additional established and emerging developers. Musculoskeletal Pain Market Outlook The future musculoskeletal pain treatment landscape is expected to favor therapies that reduce reliance on opioids, offer fewer administrations, extend the duration of pain relief, and improve mobility and quality of life. Regenerative treatments and disease-modifying candidates could reshape care in knee osteoarthritis and chronic low back pain, where existing therapies remain predominantly symptom-focused. The report evaluates therapy-level market share, peak patient share, adoption rates, sales potential, pricing, reimbursement, and market access across the seven major markets. It also assesses clinical trial activity, regulatory developments, patents, strategic partnerships, mechanisms of action, and competitive positioning for approved and investigational therapies. Report Coverage and Strategic Value <ul><li>Musculoskeletal pain epidemiology and patient population forecasts</li><li>Historical and forecast market analysis from 2022 through 2036</li><li>Current treatment practices and evolving therapeutic algorithms</li><li>Approved therapy profiles and Phase I-III pipeline analysis</li><li>Drug uptake, peak patient share, pricing, and reimbursement trends</li><li>Competitive intelligence and company-level market assessment</li><li>Unmet needs, market attractiveness, and commercial opportunities</li><li>SWOT and conjoint analysis of current and emerging therapies</li><li>Country-level insights from key opinion leaders and clinical experts</li></ul> Insights from more than 10 key opinion leaders and subject-matter experts support the report's assessment of real-world prescribing, patient adherence, treatment switching, market access, epidemiology, and future drug adoption. The findings are designed to help pharmaceutical companies, investors, healthcare organizations, and other stakeholders develop evidence-based clinical, commercial, market-access, and portfolio strategies within the global musculoskeletal pain therapeutics market. Key Topics Covered 1. Key Insights 2. Report Introduction 3. Executive Summary of Musculoskeletal Pain 4. Key Events 4.1. Upcoming Key Catalysts 4.2. Key Conferences And Meetings 4.3. Key Transactions And Collaborations 4.4. News Flow 5. Epidemiology and Market Forecast Methodology of Musculoskeletal Pain 6. Musculoskeletal Pain Market Overview at a Glance 6.1. Market Share (%) Distribution of Musculoskeletal Pain in 2025 6.2. Market Share (%) Distribution of Musculoskeletal Pain in 2036 7. Disease Background and Overview of Musculoskeletal Pain 7.1. Introduction 7.2. Types of Musculoskeletal Pain 7.3. Signs and Symptoms of Musculoskeletal Pain 7.4. Causes of Musculoskeletal Pain 7.5. Pathophysiology of Musculoskeletal Pain 7.6. Diagnosis of Musculoskeletal Pain 7.7. Biomarkers for Musculoskeletal Pain 8. Treatment of Musculoskeletal Pain 8.1. Guidelines for Management for Musculoskeletal pain 9. Epidemiology and Patient Population of Musculoskeletal Pain 9.1. Key Findings 9.2. Assumptions and Rationale: The 7MM 9.2.1. Total Diagnosed Prevalent cases of Musculoskeletal Pain 9.3. The United States 9.3.1. Musculoskeletal Pain Diagnosed Prevalent Cases in the United States 9.3.2. Musculoskeletal Pain Age-specific Cases in the United States 9.3.3. Musculoskeletal Pain Gender-specific Cases in the United States 9.3.4. Musculoskeletal Pain Total Treated Cases in the United States 9.4. EU4 and the UK 9.4.1. Musculoskeletal Pain Diagnosed Prevalent Cases in EU4 and the UK 9.4.2. Musculoskeletal Pain Age-specific Cases in EU4 and the UK 9.4.3. Musculoskeletal Pain Gender-specific Cases in EU4 and the UK 9.4.4. Musculoskeletal Pain Total Treated Cases in EU4 and the UK 9.5. Japan 9.5.1. Musculoskeletal Pain Diagnosed Prevalent Cases in Japan 9.5.2. Musculoskeletal Pain Age-specific Cases in Japan 9.5.3. Musculoskeletal Pain Gender-specific Cases in Japan 9.5.4. Musculoskeletal Pain Total Treated Cases in Japan 10. Patient Journey of Musculoskeletal Pain 11. Marketed Therapies of Musculoskeletal Pain 11.1. Marketed Competitive Landscape of Musculoskeletal Pain 11.2. ZILRETTA: Flexion Therapeutics 11.2.1. Product Description 11.2.2. Regulatory Milestones 11.2.3. Other Development Activities 11.2.4. Summary of Pivotal Trials 11.2.5. Analyst's Views 11.3. LOQOA TAPE: Taisho Pharmaceutical 11.3.1. Product Description 11.3.2. Regulatory Milestones 11.3.3. Other Development Activities 11.3.4. Summary of Pivotal Trials 11.3.5. Analyst's Views List to be continued in report. 12. Emerging Therapies of Musculoskeletal Pain 12.1. Emerging Competitive Landscape of Musculoskeletal Pain 12.2. Rexlemestrocel-L (MPC-06-ID): Mesoblast 12.2.1. Product Description 12.2.2. Other Developmental Activities 12.2.3. Clinical Development 12.2.4. Safety and Efficacy 12.2.5. Analyst's Views 12.3. TLC599: Taiwan Liposome Company 12.3.1. Product Description 12.3.2. Other Developmental Activities 12.3.3. Clinical Development 12.3.4. Safety and Efficacy 12.3.5. Analyst's Views List to be continued in the report. 13. Musculoskeletal Pain: 7MM Analysis 13.1. Key Findings 13.2. Market Outlook 13.3. Conjoint Analysis 13.4. Key Market Forecast Assumptions 13.4.1. Cost Assumptions and Rebate 13.4.2. Pricing Trends 13.4.3. Analogue Assessment 13.4.4. Launch Year and Therapy Uptake 13.5. Total Market Size of Musculoskeletal Pain in the 7MM 13.6. The United States 13.6.1. Total Market Size of Musculoskeletal Pain in the United States 13.6.2. Market Size of Musculoskeletal Pain by Therapies in the United States 13.7. EU4 and the UK 13.7.1. Total Market Size of Musculoskeletal Pain in EU4 and the UK 13.7.2. Market Size of Musculoskeletal Pain by Therapies in EU4 and the UK 13.8. Japan 13.8.1. Total Market Size of Musculoskeletal Pain in Japan 13.8.2. Market Size of Musculoskeletal Pain by Therapies in Japan 14. Unmet Needs of Musculoskeletal Pain 15. SWOT Analysis of Musculoskeletal Pain 16. KOL Views of Musculoskeletal Pain 17. Market Access and Reimbursement 17.1. United States 17.1.1. Centre for Medicare &amp; Medicaid Services (CMS) 17.2. EU4 and the UK 17.2.1. Germany 17.2.2. France 17.2.3. Italy 17.2.4. Spain 17.2.5. United Kingdom 17.3. Japan 17.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025 17.5. Musculoskeletal Pain: Market Access and Reimbursement 18. Appendix 18.1. Bibliography 18.2. Report Methodology A selection of companies mentioned in this report includes, but is not limited to: <ul><li>Flexion</li><li>Taisho Pharmaceutical</li><li>Bioventus</li><li>Mesoblast</li><li>Taiwan Liposome Company</li><li>Biosplice</li><li>Centrexion Therapeutics</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/4761313/musculoskeletal-pain-market-insight?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=wtj3wc&amp;utm_campaign=2345373+-+Musculoskeletal+Pain+Market+Report+2026-2036%3a+Growth+Drivers%2c+Epidemiology%2c+Key+Unmet+Needs%2c+Growth+Forecast&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/e73j9k</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MjRkNTQ2NmEtMmIyZi00MTk4LTk1Y2QtMDc0ODdmMmI0MWZkLTEwMjY3MzctMjAyNi0wOS0wOC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

Musculoskeletal Pain Market Report 2026-2036: Growth Drivers, Epidemiology, Key Unmet Needs, Growth Forecast

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn